Why a Durham CEO calls potential $2.7 billion deal with big pharma 'transformational'

For a drug startup that went public a year ago, an influx of cash or deal with a major pharmaceutical company can be groundbreaking, but for a Triangle gene therapy firm that just inked a deal worth up to $2.7 billion, the CEO calls it "transformational."
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news